Advertisement

Skin Cancer pp 425-434 | Cite as

Radiation Therapy in Dermatology

  • Stephan LautenschlagerEmail author
Chapter
Part of the Current Clinical Pathology book series (CCPATH)

Abstract

In spite of advances in the local treatment of malignant skin tumours and other skin diseases, radiotherapy remains highly relevant as a therapeutic alternative or under certain conditions even as the treatment of choice. Hardly any other procedure is capable of treating superficial as well as deep skin tumours with such precision according to their depth and without causing serious damage to healthy tissue. In particular, curative radiotherapy is most often used to treat basal cell carcinomas, squamous cell carcinomas, extensive precancerous lesions, lentigo maligna and lentigo maligna melanoma. Ideally, moderately to larger-sized non-melanoma skin cancers in the facial region in patients over the age of 60 are treated with radiotherapy when surgery is not feasible. Even for inflammatory skin conditions such as chronic eczema or psoriasis, radiotherapy can be performed in cases of failure of other treatment methods. Palliative radiotherapy may be indicated for Kaposi’s sarcoma and T- and B-cell lymphoma; even primary cutaneous B-cell lymphoma can be treated curatively. The radiation quality mostly used in dermatology lies between 12 and 50 kV. Knowledge of physical and radiobiological parameters is important such as half-value depth, inverse square law and absorption law. Fractionated radiotherapy is an effective and well-tolerated outpatient treatment modality which should be considered according to the exact diagnosis, age of the patient, comorbidities, goals of treatment, lesion characteristics including location and not least patient preference.

Keywords

Basal Cell Carcinoma Local Control Rate Merkel Cell Carcinoma Actinic Keratose Mycosis Fungoides 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Glossary

Absorption law

the absorption of X-rays is proportional to the thickness, density and atomic number of the material and inversely proportional to the energy of the X-ray quanta.

Electron beam radiation therapy

is a radiation therapy that uses a linear accelerator where electrons are directed to the tumour site. It has low penetration and spares deeper tissues.

Gray

it is the international energy dose unit of absorbed radiation dose of ionising radiation (IR). It is measured as the absorption of 1 J of IR by 1 kg of matter (1 Gy  =  1 J/kg).

Grenz or soft-energy (low-energy) therapy

involves exposing the skin to low-energy, non-penetrating radiation. It is mostly used in inflammatory skin conditions.

Half-value depth in tissue (HVD)

is the depth in the tissue at which the intensity of the radiation or the dose rate has been reduced to half of the surface dose rate focus-skin distance (FSD), i.e. on the length of the tube.

Half-value layer thickness (HVL)

refers to the layer thickness that reduces the intensity of the radiation to half its initial strength. It increases with hardening of the beam. It is measured in aluminium.

Inverse square law

the intensity of the dose (dose rate) of X-rays emitted from a point source is inversely proportional to the square of the distance from that source.

Ionising radiation (IR)

is the radiation that removes an electron from an atom. In medicine, it is used in radiography (diagnostic X-rays, 20–150 kV, used to obtain images from inside the body), in nuclear medicine as tracer method and in radiation therapy for its damage on DNA cells (superficial X-rays, 50–200 kV; orthovoltage X-rays, 200–500 kV; and megavoltage X-rays, 1–25 MV).

Miescher technique

it is a type of external beam radiotherapy. It involves the use of an X-ray tube with a beryllium window set at a determined energy, with the target lesion positioned at 20 cm, a 50 % depth dose at 1–1.3 of skin, a dose of 20 Gy per treatment with 5 treatments given 3–4 days apart and a 5-mm margin of normal skin included, with an accumulated dose of 10,000 rads.

Orthovoltage therapy

or, “deep” X-rays, are produced by X-ray generators, in the range of 22–500 kV and penetration of about 4–6 mm.

Palliative treatment

is the treatment to alleviate symptoms without curing the disease.

Radiation field homogeneity

refers to the homo genous dose distribution in the area of radiation

Radiation field symmetry

maximum ratio of doses at 2 symmetric points relative to the central axis of the field.

Radiation quality

is the spectrum of radiant energy produced by a given radiation source with respect to its penetration or its suitability for a specific application. It determines the depth of penetration of radiation into the tissue.

Radiation quantity

is the dose rate at the surface of the skin. It is expressed in Grays.

Radiotherapy

it is the treatment of a disease using radiation, especially by selective irradiation with X-rays or other ionising radiation and by ingestion of radioisotopes.

X-ray quanta

Individual units of X-ray energy.

References

  1. 1.
    Panizzon RG, Cooper JS. Radiation Treatment and Radiation Reactions in Dermatology. 1st ed. Berlin/Heidelberg/New York: Springer; 2004.CrossRefGoogle Scholar
  2. 2.
    Panizzon RG. Dermatologische radiotherapie. Hautarzt. 2007;58:701–10, quiz.PubMedCrossRefGoogle Scholar
  3. 3.
    Panizzon R. Radiotherapy. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick’s dermatology in general medicine. 7th ed. New York: McGraw Hill; 2008. p. 2279–84.Google Scholar
  4. 4.
    Veness MJ. The important role of radiotherapy in patients with non-melanoma skin cancer and other cutaneous entities. J Med Imaging Radiat Oncol. 2008;52:278–86.PubMedCrossRefGoogle Scholar
  5. 5.
    Zagrodnik B, Kempf W, Seifert B, et al. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer. 2003;98:2708–14.PubMedCrossRefGoogle Scholar
  6. 6.
    Schulte KW, Lippold A, Auras C, et al. Soft X-ray therapy for cutaneous basal cell and squamous cell carcinomas. J Am Acad Dermatol. 2005;53:993–1001.PubMedCrossRefGoogle Scholar
  7. 7.
    Locke J, Karimpour S, Young G, Lockett MA, Perez CA. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys. 2001;51:748–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Hernandez-Machin B, Borrego L, Gil-Garcia M, Hernandez BH. Office-based radiation therapy for cutaneous carcinoma: evaluation of 710 treatments. Int J Dermatol. 2007;46:453–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Hall VL, Leppard BJ, McGill J, Kesseler ME, White JE, Goodwin P. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol. 1986;37:33–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Rupprecht R, Lippold A, Auras C, et al. Late side-effects with cosmetic relevance following soft X-ray therapy of cutaneous neoplasias. J Eur Acad Dermatol Venereol. 2007;21:178–85.PubMedCrossRefGoogle Scholar
  11. 11.
    Veness M, Richards S. Role of modern radiotherapy in treating skin cancer. Australas J Dermatol. 2003;44:159–66.PubMedCrossRefGoogle Scholar
  12. 12.
    Feigen M. Should cancer survivors fear radiation-induced sarcomas? Sarcoma. 1997;1:5–15.PubMedCrossRefGoogle Scholar
  13. 13.
    Silva JJ, Tsang RW, Panzarella T, Levin W, Wells W. Results of radiotherapy for epithelial skin cancer of the pinna: the Princess Margaret Hospital experience, 1982–1993. Int J Radiat Oncol Biol Phys. 2000;47:451–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Motley R, Kersey P, Lawrence C. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Dermatol. 2002;146:18–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Hemminki K, Zhang H, Czene K. Time trends and familial risks in squamous cell carcinoma of the skin. Arch Dermatol. 2003;139:885–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146 Suppl 61:1–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294:681–90.PubMedCrossRefGoogle Scholar
  18. 18.
    Barta U, Grafe T, Wollina U. Radiation therapy for extensive actinic keratosis. J Eur Acad Dermatol Venereol. 2000;14:293–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Pipitone MA, Gloster HM. Superficial squamous cell carcinomas and extensive actinic keratoses of the scalp treated with radiation therapy. Dermatol Surg. 2006;32:756–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Landthaler M, Hagspiel HJ, Braun-Falco O. Late irradiation damage to the skin caused by soft X-ray radiation therapy of cutaneous tumors. Arch Dermatol. 1995;131:182–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Dupree MT, Kiteley RA, Weismantle K, Panos R, Johnstone PA. Radiation therapy for Bowen’s disease: lessons for lesions of the lower extremity. J Am Acad Dermatol. 2001;45:401–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Lukas VanderSpek LA, Pond GR, Wells W, Tsang RW. Radiation therapy for Bowen’s disease of the skin. Int J Radiat Oncol Biol Phys. 2005;63:505–10.PubMedCrossRefGoogle Scholar
  23. 23.
    Cox NH. Body site distribution of Bowen’s disease. Br J Dermatol. 1994;130:714–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Kossard S, Rosen R. Cutaneous Bowen’s disease. An analysis of 1001 cases according to age, sex, and site. J Am Acad Dermatol. 1992;27:406–10.PubMedCrossRefGoogle Scholar
  25. 25.
    Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen’s disease: 2006 update. Br J Dermatol. 2007;156:11–21.PubMedCrossRefGoogle Scholar
  26. 26.
    Moreno G, Chia AL, Lim A, Shumack S. Therapeutic options for Bowen’s disease. Australas J Dermatol. 2007;48:1–8.PubMedCrossRefGoogle Scholar
  27. 27.
    McKenna DJ, Morris S, Kurwa H. Treatment-resistant giant unilateral Bowen’s disease of the scalp responding to radiotherapy. Clin Exp Dermatol. 2009;34:85–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Bosbous MW, Dzwierzynski WW, Neuburg M. Lentigo maligna: diagnosis and treatment. Clin Plast Surg. 2010;37:35–46.PubMedCrossRefGoogle Scholar
  29. 29.
    Coleman III WP, Davis RS, Reed RJ, Krementz ET. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol. 1980;6:476–9.PubMedGoogle Scholar
  30. 30.
    Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol. 2002;146:1042–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Miescher G. Die Behandlung der Malignen Melanome der Haut mit Einschluss der Melanotischen Praecancerose. Strahlentherapie. 1960;46:25–35.PubMedGoogle Scholar
  32. 32.
    Schmid-Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol. 2000;43:477–82.PubMedCrossRefGoogle Scholar
  33. 33.
    Senff NJ, Hoefnagel JJ, Neelis KJ, Vermeer MH, Noordijk EM, Willemze R. Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol. 2007;143:1520–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Holloway KB, Flowers FP, Ramos-Caro FA. Therapeutic alternatives in cutaneous T-cell lymphoma. J Am Acad Dermatol. 1992;27:367–78.PubMedCrossRefGoogle Scholar
  35. 35.
    Sumila M, Notter M, Itin P, Bodis S, Gruber G. Long-term results of radiotherapy in patients with chronic palmo-plantar eczema or psoriasis. Strahlenther Onkol. 2008;184:218–23.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Dermatologisches Ambulatorium Stadtspital TriemliZurichSwitzerland
  2. 2.Outpatient Clinic of DermatologyTriemli HospitalZurichSwitzerland

Personalised recommendations